Hereditary Spastic Paraplegia Type 4 (Spg4) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Hereditary Spastic Paraplegia type 4 (SPG4) is the most common form of hereditary spastic paraplegia, accounting for approximately 40-50% of all autosomal dominant cases.[1] It is caused by mutations in the SPAST gene
located on chromosome 2p16.3, which encodes the protein spastin.[2] Spastin is a member of the AAA (ATPases Associated with diverse cellular Activities) family and plays a critical role in
microtubule dynamics and intracellular membrane trafficking.
SPG4 follows an autosomal dominant inheritance pattern with high penetrance.[1] However, approximately 10-20% of carriers may remain asymptomatic or have very mild symptoms.[4]
- Gene: SPAST (Spastin)
- Chromosomal location: 2p16.3
- Inheritance: Autosomal dominant
Over 200 pathogenic mutations in the SPAST gene have been identified, including missense, nonsense, frameshift, and splice site mutations.[3]
Most mutations result in a loss-of-function, leading to haploinsufficiency of spastin protein.
Spastin is primarily involved in:
- Regulates microtubule dynamics through ATP-dependent remodeling
- Promotes microtubule severing and disassembly
- Essential for axonal transport
- Facilitates endoplasmic reticulum (ER) dynamics
- Involved in autophagosome formation
- Regulates mitochondrial distribution
- Loss of spastin function leads to axonal degeneration
- Particularly affects corticospinal tract neurons
- Distal portions of long axons are most vulnerable
- Progressive spasticity - Lower limbs more affected than upper[5]
- Muscle weakness - Typically begins in distal muscles[5]
- Hyperreflexia - Exaggerated deep tendon reflexes
- Babinski sign - Present in majority of patients
- Gait disturbance - Scissor gait pattern common
- Urinary urgency or incontinence (up to 50%)
- Mild peripheral neuropathy (30-40%)
- Reduced vibration sense
- Pes cavus (high arches)
- Onset typically in second to fourth decade
- Slow progression over decades
- Most patients remain ambulatory into late adulthood
- Life expectancy generally normal
- Progressive spastic paraplegia
- Family history consistent with autosomal dominant inheritance
- Exclusion of other causes
- Gold standard: Sequence analysis of SPAST gene
- Detection rate: ~40-50% of all HSP cases
- Consider multigene panel for atypical presentations
- Other forms of hereditary spastic paraplegia (SPG3A, SPG15, SPG31)
- Primary lateral sclerosis
- Adult-onset Krabbe disease
- Vitamin B12 deficiency
- Multiple sclerosis
- Baclofen: GABA-B agonist for spasticity (oral or intrathecal)
- Tizanidine: Alpha-2 adrenergic agonist
- Botulinum toxin injections: For focal spasticity
- Anticholinergics: For urinary symptoms
- Stretching exercises
- Gait training
- Balance exercises
- Aquatic therapy
- Orthopedic surgery for contractures
- Intrathecal baclofen pump implantation
- Gene therapy approaches under investigation
- Small molecule modulators of spastin function
- Neuroprotective agents
- Prevalence: 1-9 per 100,000 worldwide
- Most common autosomal dominant HSP
- Equal distribution between males and females
- All ethnic groups affected
The study of Hereditary Spastic Paraplegia Type 4 (Spg4) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Harding AE. Classification of the hereditary spastic paraplegias. Brain. 1983;106(Pt 1):1-18.
- Hazan J, Fonknechten N, Mavel D, et al. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet. 1999;23(3):296-303.
- Errico A, Ballabio A, Rugarli EI. Spastin, the protein mutated in autosomal dominant hereditary spastic paraplegia, is involved in microtubule dynamics. Hum Mol Genet. 2002;11(2):153-163.
- Faber I, Martinez ARM, Martins CR, et al. SPG4: the most common form of hereditary spastic paraplegia. Arq Neuropsiquiatr. 2014;72(7):523-528.
- Lo Giudice M, Neri M, Falco M, et al. Generation of a mouse model of SPG4 hereditary spastic paraplegia. Dis Model Mech. 2014;7(5):493-502.
- Roll-Mecak A, Vale RD. The microtubule-destabilizing protein spastin aggregates via a domain that binds microtubules. Nat Cell Biol. 2008;10(4):415-421.
- Pantakani DV, Chtarbanova-Rudolf O, Jhunjhunwala S, et al. Role of spastin in mitochondrial function and axonal health. Cell Mol Neurobiol. 2015;35(4):503-514.
- Tarrade A, Fassier C, Courageot S, et al. A mutation in spastin is responsible for a specific form of HSP. EMBO J. 2006;25(11):2358-2367.
- Schüle R, Wiethoff S, Marti R, et al. Hereditary spastic paraplegia: clinico-genetic characteristics and refinement of mapping of the type SPG4. Brain. 2006;129(Pt 5):1146-1158.
- Fink JK. Hereditary spastic paraplegia: spastin phenotype. Neurol Clin. 2014;32(4):805-819.
- Marti R, Schüle R, Klebe J, et al. Genetic and clinical aspects of hereditary spastic paraplegia. Neurology. 2008;71(8):586-594.
- Klebe J, Schüle R. Hereditary spastic paraplegia. Nat Rev Neurol. 2012;8(10):555-567.
- Brashear A, cook JF, Weiner LJ. Intrathecal baclofen for treatment of spasticity. Phys Med Rehabil Clin N Am. 2014;25(1):93-108.
- Ruano L, Melo C, Silva MC, et al. The global epidemiology of hereditary spastic paraplegia: a systematic review. J Neurol Sci. 2014;338(1-2):77-82.